- Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-hydroxy-6-methoxy-1,5-dimethyl-, (1aS,8R,8aR,8bS)-
Violet crystals from acetone + carbon tetrachloride.
DNA alkylating cross-linking agent mitomycins.
Registry Numbers and Inventories.
Melting point, °C
182 - 184
Solubility in water
Hazards and Protection.
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Strong oxidizing agents.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
With therapeutic use - 1. Fever may occur with therapy. With therapeutic use - 1. Confusion, drowsiness, fatigue, lethargy, and weakness can occur with therapy. Teratogenic effects, effects in pregnancy, effects during breast feeding and paternal effects have been observed.
Blurred vision may occur during therapy. Ocular instillation has resulted in inflammation of the eye, ocular degeneration and glaucoma with prolonged use.
Mitomycin is only available in an injectable dosage form intended for intravenous use. The probability of oral exposure is low. Treatment should include recommendations listed in the parenteral exposure section where applicable.
Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with beta2 agonist and corticosteroid aerosols.
Remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician should examine the area if irritation or pain persists. Supportive care is all that is required. Transfusions may be necessary during leukopenic phase. Monitor patient for signs/symptoms of bleeding or infection. Interstitial pneumonia may respond to corticosteroid therapy.
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.